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Abstract
Simulation offers a simple and flexible way to estimate the power of a
clinical trial when analytic formulae are not available. The computational
burden of using simulation has, however, restricted its application to only
the simplest of sample size determination problems, minimising a single
parameter (the overall sample size) subject to power being above a target
level. We describe a general framework for solving simulation-based sam-
ple size determination problems with several design parameters over which
to optimise and several conflicting criteria to be minimised. The method
is based on an established global optimisation algorithm widely used in
the design and analysis of computer experiments, using a non-parametric
regression model as an approximation of the true underlying power func-
tion. The method is flexible, can be used for almost any problem for
which power can be estimated using simulation, and can be implemented
using existing statistical software packages. We illustrate its application
to three increasingly complicated sample size determination problems in-
volving complex clustering structures, co-primary endpoints, and small
sample considerations.
1 Introduction
The sample size of a clinical trial is typically minimised subject to the power of
the trial being above a nominal level, often 80 or 90%. For many sample size
determination (SSD) problems, power can be calculated using a simple mathe-
matical formula and the optimisation problem can be solved in a timely manner.
When complexity in the trial design or the method of analysis mean such for-
mulae are not readily available, we can estimate power using a Monte Carlo
1
(MC) approximation [1, 2]. To do so, we simply simulate several hypothetical
sets of trial data under the alternative hypothesis, analyse each of these, and
calculate the proportion of analyses which reject the null hypothesis. The sim-
plicity and flexibility of the simulation method has seen it used for a variety of
statistical models and study designs, including problems involving hierarchical
models [3, 4], proportional hazards models [5], logistic regression models [6], in-
dividual patient data meta-analyses [7, 8], patient enrolment models [9], stepped
wedge designs [10, 11], and cluster randomised crossover designs [12]. Although
calculating MC estimates of power can be computationally demanding, these
SSD problems remain feasible because, as optimisation problems, they are quite
simple. In particular, optimisation takes place over a single parameter (the
sample size), subject to a single constraint (power), and with respect to a single
objective to be minimised (the sample size again).
SSD problems, particularly those found in trials of complex interventions, are
not always this simple [13]. There may be several parameters, each influencing
the power of the trial, which need to be specified at the design stage. Several
design parameters are common in, for example, trials with multilevel structures
such as cluster randomised trials, where both the number of clusters and the
number of participants in each cluster must be specified. Increasing the number
of design parameters complicates the SSD problem by increasing the number
of possible solutions to search. A second complication arises when there is
more than one criterion we are interested in minimising, subject to the nominal
power constraint. A cluster randomised trial will often have this property, as we
would like to minimise both the total number of participants and the number
of clusters. Given multiple conflicting objectives, there is no single ‘optimum’
solution but rather a range of solutions which offer different degrees of trade-off
between the objectives. Seeking a set of good solutions, rather than a single
optimum, further adds to the difficulty of the SSD problem.
Complex SSD problems with several design parameters and several objec-
tives could in theory be solved using benchmark multi-objective optimisation
algorithms such as NSGA-II [14], robust implementations of which are freely
available in statistical software such as R [15]. However, these so-called ‘greedy’
algorithms typically assume that evaluating any proposed solution to the prob-
lem is a very fast process, and consequently evaluate many thousands of solu-
tions during the search. If these algorithms were applied to problems where eval-
uating solutions required computing an MC estimate of power, they would take
an infeasibly long time to converge. Thus, if we are to extend simulation-based
trial design to complex SSD problems, we require a more general framework
employing more efficient optimisation algorithms.
Outwith the context of clinical trial design, a great deal of research has
addressed optimisation problems where the evaluation of a solution is a compu-
tationally demanding, or expensive, operation [16, 17]. One approach addresses
the problem by substituting the expensive function with a mathematical ap-
proximation known as a surrogate model. The surrogate model is then used to
make predictions about the true function for different values of design param-
eters, with these predictions informing which point should be evaluated next.
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The information obtained from this evaluation is used to update the surrogate
model, thus improving the predictions available at the next iteration. One class
of surrogate model is Gaussian process (GP) regression. Also known as Kriging
and having its roots in geostatistics [18], GP models are spatial interpolators
which are computationally tractable [19] and can be fitted using robust and
freely available software [20]. A GP surrogate model provides not only a predic-
tion of the true function value at any point, but also a measure of uncertainty
in this prediction. This property is exploited by the benchmark Efficient Global
Optimisation (EGO) algorithm [21], allowing the next point in the search to
be chosen in a way that formally balances the potential benefits of exploitation
(searching around areas already known to be promising) and exploration (search-
ing in areas of high uncertainty). Although EGO was originally proposed for
unconstrained optimisation of expensive objective functions with deterministic
output, various proposals have extended it to incorporate the expensive con-
straints [22], multiple objectives [23], and stochastic outputs [24] that feature
in complex SSD problems.
In this paper we will explore how GP regression models and a variant of the
EGO algorithm can be used to solve complex SSD problems. In contrast with
many of the available methods and software for simulation-based SSD, which
focus on specific application areas such as multilevel designs (MLPowSim [25]),
IPD meta-analyses (ipdpower [8]) or stepped wedge design (SWSamp [10]), we
take the same approach as that used in the SimSam package [4] and propose a
more general framework which can be applied to a broad class of SSD problems
following the Neyman-Pearson hypothesis testing formulation. Specifically, we
require that the user can write a program which simulates the data generating
process and analysis of the trial, returning a binary indicator denoting rejec-
tion or otherwise of the null hypothesis. This flexibility will not only mean
simulation-based SSD can be used for a wide range of existing trial designs,
but will also facilitate SSD for novel designs developed in the future and which
cannot be anticipated now.
The remainder of the paper is structured as follows. Three motivating prob-
lems are described in Section 2. In Section 3 we provide the necessary back-
ground and notation regarding Monte Carlo estimation and multi-objective op-
timisation. In Section 4 we describe Gaussian process regression, the efficient
global optimisation algorithm, and a framework for its application to sample
size determination. We return to the examples in Section 5, illustrating how
the method can be applied in practice. We conclude with a discussion of the
implications and limitations of the proposed approach in Section 6.
2 Motivating examples
‘Pacing, graded Activity, and Cognitive behaviour therapy; a randomised Eval-
uation’ (PACE) [26, 27] was a randomised controlled trial comparing adaptive
pacing therapy (APT), cognitive behavioural therapy (CBT), graded exercise
therapy (GET) and specialist medical care (SMC) as secondary care treatments
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for patients with chronic fatigue syndrome (CFS/ME). The data had a complex
multilevel structure, with three of the four arms including a therapy provided
by different therapists (partially nested structure) and all arms including med-
ical care from the same doctors (crossed structure), leading to the potential for
treatment-related clustering. Since some participants receive treatment from
both a therapist and a doctor, the relationship between participants and care
providers is cross-classified. Moreover, two potentially correlated co-primary
endpoints (fatigue and disability) were used. The original sample size calcula-
tion used a simple analytic formula for comparing proportions in two groups
of equal size. As was typical at the time, it did not account for the impact
of clustering or of simultaneously analysing two correlated endpoints. In this
section we will describe three theoretical example SSD problems based around
the PACE trial, increasing in complexity at each step.
2.1 Complex clustering
For simplicity, we consider redesigning the PACE trial to detect a difference
in the probability of participants responding with respect to fatigue between
the APT and SMC arms. A participant is considered to have responded if
they have a score of 3 or less (indicating normal fatigue) on the likert Chalder
Fatigue Scale (CFS) [28]. As in the original design, we assume an equal number
n of participants will be recruited to each arm. In the intervention arm, k
therapists will deliver APT to participants, with each participants receiving
treatment from a single therapist. We assume that the number of participants
allocated to each therapist will vary with therapist. Specifically, we model the
proportion of all participants in the APT arm allocated to a therapist using a
Gamma distribution with shape parameter 1. Participants in both APT and
SMC arms will receive specialist medical care from one of 2k doctors, with the
proportion allocated to each doctor also following a gamma distribution with
shape parameter 1. This leads to a multilevel data structure where therapists are
partially nested within interventions, doctors are crossed with interventions, and
patients are cross-classified with therapists and doctors in the intervention arm
and nested within doctors in the control arm [29]. This structure is illustrated
in Figure 1.
In this example, the primary analysis will be a logistic mixed effect model
with a likelihood ratio test of the null hypothesis that the probability of response
in the APT arm, p1, is equal to that in the SMC arm, p0. For simplicity,
the model includes random intercepts in the linear predictor for doctor effects
and a random coefficient for therapist effects. Further work is needed on the
model that is recommended in this scenario but as the model we assume is
for illustration purposes only, it could simply be updated once a recommended
model becomes available. We assume that the test statistic follows a chi-squared
distribution with 1 degree of freedom, and therefore that the type I error rate can
be controlled at a nominal level of α∗ = 0.05 (two-sided). As model convergence
may be an issue, we include this in our definition of power by not rejecting the
null hypothesis when the model fails to converge. We require that the power at
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Figure 1: Multilevel structure of the SMC and APT arms of our example,
where therapists (T) are partially nested within interventions, doctors (D) are
crossed with interventions, and patients (P) are cross-classified with therapists
and doctors in the intervention arm and nested within doctors in the control
arm.
the alternative hypothesis H1 : p0 = 0.1, p1 = 0.25 be no less than 90%. Subject
to these constraints, we aim to find minimal values of n and k, recognising that
these two objectives will conflict with one another.
Although sample size formulae for partially nested designs with binary out-
comes are available [30], they do not extend to the structure in this example
where participants are cross-classified and doctors are crossed with interven-
tions. Including the complex process of model non-convergence into the defini-
tion of power further necessitates the use of simulation.
2.2 Co-primary endpoints
We extend the previous example to include a co-primary endpoint relating to
disability, a binary response defined as 75 (out of 100) or more on the short
form-36 physical function subscale [31], where the mean score for the UK adult
population is around 85. An in PACE, the endpoints will be analysed separately,
each time fitting a logisitc mixed effect model and conducting a likelihood ratio
test as described in Section 2.1. The results of the trial will be considered posi-
tive only if both of the analyses show a statistically significant difference, leading
to reduced power under the alternative hypothesis of an effect on each endpoint
in comparison to the univariate case of Section 2.1[32]. Correlation between the
endpoints is expected at the participant level, and correlations between the ran-
dom effects of therapists and doctors for different endpoints are also expected.
This correlation will be modelled in the data generating process, but not in the
analysis due to concerns about the feasibility of fitting a multivariate model.
Such a mismatch between the data generating and analysis models has been
noted as a clear motivation for simulation-based power calculations [2].
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2.3 Small sample pilot
Finally, we consider how we might have designed a pilot trial prior to the defini-
tive PACE trial to provide a preliminary test of potential efficacy. At this early
stage, we would like 90% power to detect a meaningful effect in either the fa-
tigue or disability endpoints. To enable a small trial to have such high power,
we relax the type I error rate to 0.2 (one-sided) and change the primary end-
points from binary responses to the continuous scores on the CFS and SF-36.
In the pilot setting we assume we have greater control over the numbers of par-
ticipants allocated to therapists and to doctors, and so can maximise efficiency
by balancing cluster sizes. We also now consider varying the number of doctors.
Our objectives are to minimise the total number of participants, the number of
therapists, and the number of doctors. The small sample setting of a pilot trial
implies the distributional assumptions underpinning type I error control may
be violated, and so we simulate power under the null hypothesis and model this
constraint in addition to power under the alternative. We include the nominal
type I error rate used when testing the null hypothesis as a design variable, al-
lowing an appropriate adjustment to be made as part of the larger optimisation
process.
In terms of design parameters, we must choose the total sample size in the
APT arm, denoted n1; the number of APT therapists, k; the allocation ratio
relating the total number of participants in each arm, r = n0/n1; the number of
doctors, j; and the nominal type I error rate, a. Thus, in comparison with the
preceding examples, the number of designs to be searched over is significantly
larger. By requiring the simulation of power under the null and alternative
hypotheses, the computational burden of simulation is doubled. By minimising
three objectives simultaneously, a larger set of solutions will be required to
enable the available trade-offs between them to be fully appreciated.
3 Background
3.1 Monte Carlo estimation
Monte Carlo methods can be used to numerically approximate expectations
E[f(Z)] of real valued functions f(Z) with respect to the probability distribution
of Z. Given N samples of Z, denoted zi, i = 1, . . . , N , the MC estimate is
E[f(Z)] ≈ 1
N
N∑
i=1
f(zi). (1)
The estimate is unbiased for all N and has variance equal to
ω2 = V ar
[
1
N
N∑
i=1
f(zi)
]
=
1
N
V ar [f(zi)] . (2)
The standard error of the MC estimate will therefore reduce at a rate of 1/
√
N
as we increase N . When N is large we can consider an MC estimate to be
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the true expectation plus a normally distributed error term with 0 mean and
variance ω2, i.e.
1
N
N∑
i=1
f(zi) = E[f(Z)] + e, where e ∼ N(0, ω2). (3)
In the context of simulation-based trial design, if Z is the test statistic to be
compared with an acceptance region Λ then the probability of acceptance under
hypothesis H is E[I(Z ∈ Λ) | H ], where I(.) is the indicator function. An MC
estimate of the power of a trial design under H can therefore be obtained given
N test statistics z1, . . . , zN sampled under H . The steps required to simulate
these statistics are described in [2], and we briefly summarise them here:
1. Define the population model. This describes the underlying target popula-
tion and should specify all population parameters and distributions under
the hypothesis of interest.
2. Define the sampling strategy. This should specify the numbers of patients,
clusters, or any other sampling units in the trial and how they will be
drawn from the population.
3. Define the method of analysis. For hypothesis testing, this will include
defining the form of the test statistic Z and the acceptance region Λ.
Given each of the above elements, pseudo-random number generators can be
used to simulate the recruitment, randomisation and primary outcome measure
of patients under the hypothesis of interest, from which a test statistic zi can
be calculated.
3.2 Multi-objective optimisation
A solution to the SSD problem consists of a vector of design parameters x, and
the solution space X is the set of all solutions. A simple SSD problem may have
a 1-dimensional solution space, while more complex problems may have several
dimensions. Elements of x may include parameters defining the sample size of
the trial, the acceptance region to be used in the analysis, or any other design
aspect over which we have control and which may influence the trial operating
characteristics. For instance, in example 2.1 a solution x = (k, n) is defined by
the number of participants in each arm (n) and the number of therapists in the
intervention arm (k).
An objective function f(x) is a function f : X → R which we wish to
minimise. In a multi-objective problem with B objectives, we denote the vector
of objective values as y = (f1(x), . . . , fB(x)) ∈ RB. We will describe RB as
the objective space. In our example 2.1, we have two objectives: minimising the
number of clusters f1(x) = k; and minimising the total number of participants,
f2(x) = 2n.
A constraint function g(x) is a function g : X → R which must be less than
or equal to 0 for the solution x to be considered feasible. For example, if type
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II error rate is denoted by β(x) and the nominal type II error rate is set at
β∗, a constraint function would be g(x) = β(x) − β∗. We denote C constraint
functions as gj(x), j = 1, . . . , C. The general SSD problem can now be stated
as
min
x∈X
fi(x), i = 1, . . . , B (4)
subject to gj(x) ≤ 0, j = 1, . . . , C. (5)
We denote by ≺ the relation of Pareto dominance, where a solution domi-
nates another if it is at least as good in all respects, and better in at least one.
Formally, x∗ ≺ x if fi(x∗) ≤ fi(x) for i = 1, . . . , B, and fj(x∗) < fj(x) for
some j. For instance, xa = (n = 100, k = 10) ≺ xb = (n = 120, k = 10) in
example 2.1, but xa = (n = 100, k = 10) ⊀ xc = (n = 80, k = 13). The Pareto
set is the set of non-dominated solutions Xp = {x ∈ X | ∄ x∗ ∈ X s.t. x∗ ≺ x}.
An example Pareto set for example 2.1 is plotted in Figure 2, illustrating the
available trade-offs between the two objectives.
Multi-objective optimisation seeks to find a set of solutions that are close to
the true Pareto set, with every member of the set non-dominated with respect
to all other members. We will refer to these as approximation sets, denoted A.
That is, any set A such that A ∈ X with ∀ x ∈ A : ∄ x∗ ∈ A : x∗ ≺ x is
an approximation set [23]. A set A is feasible if all constraints are satisfied by
every member of A. An example feasible approximation set for example 2.1,
plotted in Figure 2, is given by the four (2n, k) points
A = {(589, 24), (705, 20), (810, 12), (982, 10)}. (6)
To understand the similarity between any approximation set A and the ideal
Pareto set, we measure its dominated hypervolume. This is the volume of the
subspace dominated by solutions in A and bounded by a reference point r:
H(A) = Vol({y ∈ RB | y is dominated by some y∗ ∈ A and y ≺ r}). (7)
The largest possible hypervolume of any feasible approximation setA is achieved
by the true Pareto set Xp. We can therefore frame the multi-objective optimi-
sation problem as finding the feasible approximation set A with largest hy-
pervolume. Taking a reference point of r = (1200, 30) (marked by the cross
in Figure 2), our example approximation set has a dominated hypervolume of
9202. This can be compared with that of the Pareto set, at 14501. We would
expect the approximation set to converge to the Pareto set as the number of
optimisation iterations increases.
4 Simulation-based sample size determination
4.1 Overview
The proposed method is based on the Efficient Global Optimisation algorithm [33].
For clarity we will describe the algorithm in the context of an SSD problem
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Figure 2: Example Pareto front Xp and approximation set A for a cluster ran-
domised trial design problem. The dominated hypervolume of the approxima-
tion set with respect to a reference point (cross) is the shaded area.
with a single constraint function, denoted g(x), which must be estimated us-
ing simulation. The more general case of several constraints will follow. The
initial step is to select a number of potential solutions to the SSD problem
XE = (x(1), . . . ,x(E)) and evaluate the constraint function at each of these
points, giving yE = (g(x
(1)), . . . , g(x(E))). A Gaussian process regression model
is then fitted to the data, relating the solutions XE to the estimates yE and
providing an approximation of the constraint function g. The solution x∗ which
has the largest expected improvement EI(x) according to the predictions of
the GP model, is then found. This solution is evaluated to obtain y∗. This
new data is then used to update the GP model, which is then used again to
find the next solution to evaluate. The algorithm can be repeated until either
the computational resources available have been exceeded, or until no further
improvements are being obtained. The Algorithm is summarised in 1 below.
Algorithm 1 Efficient Global Optimisation [33]
1: Compute MC estimates yE = (g(x
(1)), . . . , g(x(E)))
2: while Computation budget not exhausted do
3: Regress yE on XE = (x(1), . . . ,x(E))
4: Find x∗ = argmaxEI(x)
5: Compute MC estimate y∗ = g(x∗) and add to yE, XE
6: Update the computational budget
7: end while
The process of computing MC estimates used in steps (1) and (5) has already
been described in Section 3.1. In what follows we will first consider step (3),
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describing Gaussian process regression models and outlining how they can be
fitted and used to make predictions. The notion of expected improvement in
step (4) will then be defined for the constrained multi-objective problems we
are concerned with. Finally, we cover the remaining aspects of implementation.
4.2 Gaussian process regression
Consider a set of points XE = {x(1), . . . ,x(E)} ⊂ X at which an expensive
function g will be estimated using the Monte Carlo method. Consider also
some other point x∗ 6∈ XE where we are interested in making a prediction of
g(x∗). The value of g at each point in {XE ,x∗} is initially unknown, but can
be modelled by a Gaussian process (GP).
In using a GP we assume that our belief regarding the the values of g can
be represented by a multivariate normal distribution. Prior to computing any
estimates of g, we assume that the mean function of this multivariate normal is
equal to zero1. We write the covariance matrix of the distribution as(
K(XE ,XE) K(XE ,x∗)
K(x∗,XE) K(x∗,x∗)
)
, (8)
where K(XE ,XE) is the E × E covariance matrix for the points XE , k∗ =
K(XE ,x∗) = K(x∗,XE) is the E-length vector of covariances between XE and
x∗, and K(x∗,x∗) is the variance at x∗.
Given this prior distribution, we compute the MC estimates y(1), . . . , y(E)
at each point in XE . From equation (3), y(i) = g(x(i)) + e(i) where e(i) is a
zero-mean normally distributed error term with standard deviation ω(i). We
denote by ∆ the E × E diagonal matrix where the ith entry is [ω(i)]2. The
distribution of g(x∗) conditional on the observed y can be shown to be normal
with mean k⊤∗ (K+∆)
−1y and variance k(x∗, x∗)−k⊤∗ (K+∆)−1k∗ [19]. Thus,
given a prior covariance matrix of the form (8) and some MC estimates of g at
the points XE , a conditional predictive distribution of g(x∗) can be found. It is
this distribution which will be used in the optimisation algorithm when deciding
which solution should next be evaluated.
The predictive distributions are influenced by the prior covariance matrix
(8). The matrix is populated using a covariance function (or kernel), k(x,x′) :
X × X → R. This function must be symmetric and positive definite for the
covariance matrix to have the same properties. One such covariance function is
the squared exponential, which has the form
k(x,x′) = σ exp

− D∑
j=1
(xj − x′j)2
λ2j

 . (9)
By using covariance functions of this form we will obtain a Gaussian process
which is infinitely differentiable over X and thus very smooth. This would
1This is not a restrictive assumption. After observing estimates of the function g and
updating the GP model to account for these, the mean function can take on non-zero values.
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Figure 3: A Gaussian process model of a power function over a one-dimensional
sample size (solid line) based on three evaluations. Uncertainty is shown as the
shaded area. Expected improvement (dotted line) is maximised at a sample
size of 190, where the predicted power is normally distributed around a mean
estimate of 0.84 (dashed line).
appear to be a reasonable restriction to place upon the power functions we
are interested in. In order to populate the covariance matrix we must choose
values of the hyper-parameters θ = (σ, λ1, . . . , λD). We do this by numerically
optimising the log marginal likelihood
log p(y | XE , θ) = −1
2
y⊤[K +∆]−1y − 1
2
log |K +∆| − n
2
log 2pi, (10)
considered as a function of θ [19]. Fitting a GP model by maximum likelihood
in this manner can be done using the function km in the R package DiceKriging,
as illustrated in the appendix.
An illustration of a Gaussian process regression model of a power function
in one dimension is given in Figure 3. The power of three different choices of
sample size have been calculated and a GP model fitted to the results. The
figure illustrates how the uncertainty in the model predictions (shaded area)
increases the further we are from a point which has been evaluated. The GP
prediction of power at a sample size of n = 190, shown as a dashed line, is
normally distributed with mean 0.84 and standard deviation 0.035.
4.3 Expected improvement
At any given point during the optimisation process we can obtain an approx-
imation set A based on the set of solutions which have been evaluated up to
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that point. If a new point x∗ is considered feasible, a new approximation set
A∗ will be identified. The improvement resulting from the evaluation of x∗ is
the difference in the dominated hypervolumes:
I = H(A∗)−H(A). (11)
Prior to evaluation, we do not know if the point x∗ will be considered feasible.
We therefore modify I to account for the probability that x∗ will be considered
feasible after the MC estimates have been obtained. This probability can be
estimated using the GP regression methodology described in Section 4.2. A GP
model of unknown constraint function g will describe our current belief about
the value of g at x∗ using a normal distribution with mean m and variance
s2 g(x∗) ∼ N (m, s2), and we will consider the point x∗ feasible if the upper
100× p% quantile of this distribution is below 0. We denote this quantile as
q(x∗) = m+Φ
−1(p)s, (12)
where Φ is the standard normal cumulative distribution. Following an evaluation
of x∗ the GP model will be updated and the quantile revised to q+(x∗). Before
the evaluation the value of q+(x∗) is unknown, but it is shown in [24] that its
predictive distribution is q+(x∗) ∼ N(m+, s2+) where
m+ = m+Φ
−1(p)
√
ω2s2
ω2 + s2
(13)
s2+ =
[s2]2
ω2 + s2
, (14)
and ω is the MC error of the planned evaluation, estimated asm(1−m)/N where
N is the number of MC samples to be used. The predictive distribution can then
be used to calculate the probability that the point x∗ will be considered feasible
following its evaluation. Following [22], we multiply the theoretical improvement
I by this probability, thus penalising candidate solutions with a low chance of
satisfying the constraint. This then gives us our expected improvement measure
EI, where
Expected Improvement EI(x∗) = [H(A∗)−H(A)]
C∏
j=1
Φ
(−mj,+
sj,+
)
. (15)
Note that we include a penalty term for all j = 1, . . . , C constraint functions.
This maximisation problem is in itself complex, with a potentially large number
of local maxima. We therefore use the particle swarm optimisation algorithm
as implemented in the R package pso [34], designed to avoid becoming trapped
in local maxima, to solve this sub-problem.
An illustration of expected improvement for a single-objective problem is
given in Figure 3. When choosing which sample size to evaluate next and
aiming to find the lowest per-arm sample size with at least 80% power, we
balance the potential improvement over the best current solution (a sample size
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of 260) with the probability of constraint satisfaction. In this case, we would
choose to evaluate the sample size of 190, estimated by the GP model to have
a power of 84%.
4.4 Implementation
To apply Algorithm 1 in practice we must first choose the initial set of points
to be evaluated, XE . One recommendation is to include 10 points for each
dimension of the solution space, and to allocate between 30 and 50% of the total
computation budget to their evaluation[35]. To select the location of the points
in XE we use the space-filling Sobol sequence generated using the R package
randtoolbox [36]. The number of iterations and the number of MC samples
N used at each iteration must also be chosen. Given a total computational
budget in terms of MC samples, the choice of these values should account for
the fact that fitting GP regression models in R to more than around 800 points
is currently infeasible [37].
As the algorithm depends on GP regression models, it can be helpful to
assess the fit of these models. One approach is to regularly plot the predicted
mean and standard deviation in one or two dimensions, centred at the last
evaluated point. Poor model fit could be identified if the mean function is not,
for example, strictly increasing as expected. We can also contrast the predicted
function values with the obtained function values at each iteration, halting the
algorithm if a large and unexpected discrepancy in these values is observed.
We have used R to implement the proposed framework, partly due to the
availability of robust and efficient R packages for fitting Gaussian process models
(DiceKriging [20]) and for global optimisation (pso [34]). Using R also provides
flexibility in terms of the user-writen simulation routines by facilitating various
complicated analysis procedures, e.g. multilevel modelling through lme4 [38].
Our implementation works to a simple interface. The user must provide in-
stances of two data frames. The first, design_space, contains a row for each
design parameter describing its name and its lower and upper bounds. The
second, constraints, contains a row for each constraint function gj . Each row
should include a label for the constraint, the hypothesis it pertains to, a nomi-
nal power which should not be exceeded, and the confidence we require in the
constraint being satisfied (i.e. the p in Equation 12). Further, two functions
are required. The first, objectives, takes as its argument a vector of design
parameter values x and returns a vector of objective values (f1(x), . . . , fB(x)).
The second, sim_trial, takes as its arguments a vector of design parameter
values x and a vector of parameter values defining the conditions under which
we wish to simulate. The function should simulate the necessary data gener-
ation and analysis and return a boolean indicator of the rejection of the null
hypothesis, or, more generally, of declaring ‘success’. Given these components,
the example R code in the appendix can be modified to solve the problem at
hand.
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5 Application to the examples
In this section we describe the data generating models used to simulate trial
data for each of our examples and the methods used in their analyses. Full
details, including all the programs used to generate the results presented, are
given in the appendix.
5.1 Complex clustering
We model the binary response of the ith participant using a latent variable
representation. Specifically, we suppose that underlying the binary response yi
there is a continuous latent variable y∗i such that
yi =
{
1 if y∗i ≥ 0
0 if y∗i < 0.
As before, we define our model in terms of the y∗i . Using the multilevel model
notation of [39]:
y∗i = β0 + β1ti + u
(2)
therapist(i)ti + v
(2)
doctor(i) + ei (16)
u
(2)
therapist(i) ∼ N(0, σ2T ) (17)
v
(2)
doctor(i) ∼ N(0, σ2D), (18)
where ei is a level 1 residual with mean zero and variance σ
2
W . Assuming ei
follows a logistic distribution with σ2W = 3.29 leads to a random intercept logistic
model.
For the purposes of power calculations we must make some assumptions
about the various nuisance parameter values. We set the 2nd level variance
components to σ2T = 0.19, σ
2
D = 0.37 in order to give a variance partition co-
efficient of σ2D/(σ
2
D + σ
2
W ) = 0.1 in the control arm, a typical value in this
setting. Similarly, the variance partition coefficient for between-therapist vari-
ance is then σ2T /(σ
2
T + σ
2
D + σ
2
W ) = 0.05, and for between-doctor variation,
σ2D/(σ
2
T + σ
2
D + σ
2
W ) = 0.095. Recall that we want to simulate the power of the
trial under the alternative hypothesis H1 : p0 = 0.1, p1 = 0.25. We can translate
these probabilities into corresponding values for the coefficients in our model,
giving H1 : β0 = log(p0/(1− p0)) = −2.20, β1 = log(p1/(1− p1))− β0 = 1.10.
The design parameters are the number of participants in each arm n, the
number of therapists k in the APT arm, and the number of doctors j delivering
specialist medical care across both arms. For simplicity and ease of illustration
we will fix j = 2k. When searching over the remaining design parameters
n and k we will initially consider n ∈ [100, 500] and k ∈ [3, 30], noting that
these can be easily revised if the initial evaluations indicate larger values are
required to achieve nominal power. We wish to minimise both the total number
of patients f1(x) = 2n and the total number of care providers f2(x) = 3k.
The only constraint we must satisfy is that the type II error rate β(x) under
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the alternative hypothesis is no more than β∗ = 0.1. This gives the constraint
function g1(x) = β(x) − 0.1.
The original PACE sample size calculation did not account for clustering and,
using simple analytic formulae for power of test of proportions, arrived at n =
135 per arm (before inflating for attrition) to achieve 90% power. Simulating
the actual power obtained from n = 135 under our proposed model, with k =
10 therapists and j = 20 doctors, gave an MC estimate of 0.69 power (95%
confidence interval 0.66 to 0.72). Fitting two multilevel models for each sample
led to a significant computational burden, needing over 5.3 minutes to generate
the N = 1000 samples required for this estimate. Thus, there is a need to
search for an appropriate sample size using simulation, but a practical limit on
the number of designs which we can evaluate in a timely manner.
We initialised the optimisation algorithm by generating a Sobol sequence of
size 20 and computing MC estimates of power for each point using N = 100
samples. Following this, 30 iterations of the algorithm were applied, with N =
100 samples used at each iteration. We chose these optimisation parameters to
ensure a solution could be found quickly, noting that further iterations can easily
be added if solutions of a higher quality are sought. In Figure 4 we plot the 50
evaluated solutions, distinguishing between those in the initial design XE , those
which were subsequently evaluated during the iterative phase of the algorithm,
and those which together form the final approximation set. The contours of the
mean function of the final GP model are also shown.
For comparison, we also plot the approximation set obtained using a similar
procedure as that implemented in MLPowSim, software designed for simulation-
based SSD for problems with multilevel data. Specifically, we take a Sobol se-
quence of size 50 and estimated the type II error at each of these points using
N = 100 MC samples. For each point a 95% confidence interval based on the
MC error was calculated, and any points where the interval was not entirely
below the nominal value of 0.1 were discarded. Of those that remained, any
dominated solutions were discarded. The remaining two solutions are plotted in
Figure 4. The proposed method has led to solutions of higher quality which col-
lectively dominate those produced by the simpler method, with lower numbers
of participants, providers, or both.
At the ith iteration of the algorithm we calculated the dominated volume
H(Ai), plotted in Figure 5. In this instance the algorithm appears to success-
fully improve the quality of the approximation set as the number of iterations
increases, with the rate of improvement decreasing over time. The total run-
ning time was 47 minutes. Note that H(Ai) is not strictly increasing. This
is because the evaluation of a new solution can lead to revised estimates of
other solutions which were in the approximation set, such that they are then
considered infeasible and removed from the set.
The solutions which form the final approximation set are detailed in Table 1.
As few as 6 therapists and 12 doctors can lead to a sufficiently powered trial,
although 742 participants in total are required in this configuration. On the
other hand, if minimising the total sample size is deemed more important than
minimising the number of therapists and doctors, we see that as few as 546
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Figure 4: Objective values of solutions in the initial set XE (open circles), subse-
quent iterations of the algorithm (crosses), and those in the final approximation
of the Pareto set (filled squares). The approximation set obtained using a fixed
design is also shown (filled circles). Contours represent the mean function of
the final GP model.
1600
1700
1800
1900
2000
2100
0 10 20 30
Iteration
D
om
in
at
ed
 h
yp
er
vo
lu
m
e
Figure 5: Quality of the approximation set obtained as the algorithm proceeds,
where higher dominated hypervolume reflects higher quality.
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Table 1: Approximation set after 30 iterations for Example 1. Solutions are defined
by their total sample size 2n, number of therapists k, and number of doctors j.
Type II error rate β is constrained to be below 0.1, while the total sample size and
number of providers are to be minimised.
2n k j β (s.e.), N = 102 β (s.e.), N = 504
742 6 12 0.11 (0.031) 0.093 (0.003)
678 7 14 0.1 (0.03) 0.081 (0.003)
626 8 16 0.11 (0.031) 0.087 (0.003)
604 9 18 0.09 (0.029) 0.077 (0.003)
564 10 20 0.06 (0.024) 0.081 (0.003)
546 12 24 0.09 (0.029) 0.084 (0.003)
participants are necessary providing 12 therapists and 24 doctors are included.
The approximation set contains 6 solutions in total, providing a reasonable set
of options from which the solution best representing the priorities of the decision
makers can be selected.
As can be seen from Table 1, approximate upper 95% confidence limits based
on the initial N = 102 MC estimates of power often exceed the corresponding
nominal bound of 0.1. For example, the solution described in the first row would
have an approximate upper 95% two-sided confidence interval of (0.049, 0.171).
To verify the actual type II error we computed a more precise MC estimates
using N = 504 samples, which gave an estimate of 0.093 and a two-sided interval
of (0.087, 0.099). Similar results are seen for the remaining solutions in the
approximation set, as shown in Table 1. This demonstrates the GP’s ability to
share information of MC estimates computed at several points to increase the
precision at each of them.
5.2 Co-primary endpoints
For our second example we consider a second co-primary binary responder end-
point. We use the same latent variable representation as described in the pre-
ceding section to model the fatigue response yFi and disability response y
D
i of
the ith participant. Correlation between these two endpoints is modelled by
simulating bivariate residuals (eFi , e
D
i ) from a joint logistic distribution with
correlation ρW and marginal variances σ
2
e = 3.29 as before. We also allow
for correlation between the random effects associated with each therapist and
doctor. These are now simulated according to the bivariate normal distributions
(uFtherapist(i), u
D
therapist(i)) ∼ N
(
(0, 0)T ,
(
σ2T ρTσ
2
T
ρTσ
2
T σ
2
T
) )
(vFdoctor(i), v
D
doctor(i)) ∼ N
(
(0, 0)T ,
(
σ2D ρDσ
2
D
ρDσ
2
D σ
2
D
) )
We set all correlations equal at ρW = ρT = ρD = ρD = 0.9, reflecting a situation
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Figure 6: Objective values of solutions in the initial set XE (open circles), subse-
quent iterations of the algorithm (crosses), and those in the final approximation
of the Pareto set (filled squares).
where both a patient’s responses and the individual therapist and doctor effects
and very similar for both the fatigue and disability outcomes.
The algorithm was applied using the same settings as before, with an initial
design of 20 points followed by 30 iterations, and each evaluation using N = 100
MC samples. The run time in this case was 96 minutes, roughly double that
of the previous example due to each simulation fitting twice as many models.
The resulting approximation set is plotted in Figure 6. Again, the contours
represent the mean function of the final GP model.
Table 2 provides full details of the obtained approximation set together with
their initial MC estimates of type II error rate using N = 102 MC samples,
and further estimates using N = 504 MC samples. Approximate 95% confi-
dence intervals around the more precise estimates all either include the nominal
constraint of 0.1, or lie entirely below it.
5.3 Small sample pilot
For our final example, recall that we have two continuous co-primary endpoints.
For notational simplicity we use model (16) but now consider the y∗i to be the
actual observed continuous response, as opposed to a latent variable. We now
assume the individual-level residual term ei is normally distributed but with the
same variance as before, thus maintaining the variance partition coefficients at
the same levels. The alternative hypothesis remains H1 : β1 = 1.10. Note that
this corresponds to a treatment effect standardised with respect to the total
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Table 2: Approximation set after 30 iterations for Example 2. Solutions are defined
by their total sample size 2n, number of therapists k, and number of doctors j.
Type II error rate β is constrained to be below 0.1, while the total sample size and
number of providers are to be minimised.
2n k j β (s.e.), N = 102 β (s.e.), N = 504
846 9 18 0.12 (0.033) 0.069 (0.003)
638 10 20 0.09 (0.029) 0.104 (0.003)
624 12 24 0.09 (0.029) 0.096 (0.003)
standard deviation in the APT arm of 1.10/
√
(0.19 + 0.37 + 3.29) = 0.56.
Our design parameters (together with the ranges considered) are the total
sample size in the APT arm, denoted n1 (50 to 100); the number of APT ther-
apists, k (2 to 10); the allocation ratio relating the total number of participants
in each arm, r = n0/n1 (0.5 to 1.5); the number of doctors, j (3 to 20); and
the nominal type I error rate to be used in the hypothesis tests, a (0.05 to 0.2).
The three objective functions to be minimised are f1(x) = n1 + rn1, f2(x) = k
and f3(x) = j. The two constraints to be satisfied are g1(x) = β(x) − 0.1 and
g2(x) = α(x) − 0.2.
Given the increase in dimensions of the solution space, we use an initial
Sobol sequence design of 50 solutions. As before, we use 100 MC samples
for each evaluation. After 50 iterations of the algorithm, an approximation
set containing 15 solutions was obtained. The algorithm took 2 hours and 36
minutes to run. The objective values of these solutions are illustrated in Figure
7, with full details provided in Table 3. The total number of participants ranged
from 140 to 214; of therapists, from 5 to 10; and of doctors, from 5 to 23. Type
I error rates ranged from 0.09 to 0.14, all some way below the actual constraint
value of 0.2. We calculated precise MC estimates (using N = 504 samples)
of both type I and II error rates for each solution in the approximation set.
As shown in Table 3, type II error rates all appear to be around or slightly
below the constraint of 0.1. Type I error rates, in contrast, are in some cases
significantly below the constraint of 0.2. This suggests there is some potential
for improvement in the approximation set by applying further iterations of the
algorithm.
6 Discussion
Although simulation is often required for clinical trial sample size determination,
related methodology has typically assumed that there is only one parameter
which we are able to adjust (the sample size); that there is only one operating
characteristic which must be estimated using simulation (the power of the trial);
and that our goal is to minimise only one criterion (the sample size again) [2, 4].
In this paper we have described a flexible approach to simulation-based SSD
which can be used for more general multi-parameter problems. The method
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Figure 7: Objective values of the approximation set obtained following 50 iter-
ations of the algorithm for Example 3.
Table 3: Approximation set after 50 iterations for Example 3. Solutions are defined
by the number of participants in the APT arm n1, the total number of participants
across both arms n, the number of therapists k, the number of doctors j, and the
nominal type I error rates a. Both Type I and II error rates are estimated using
simulation using N samples, and are constrained at 0.2 and 0.1 respectively.
N = 102 N = 504
n1 n k j a β (s.e.) α (s.e.) β (s.e.) α (s.e.)
94 202 5 15 0.11 0.07 (0.026) 0.12 (0.033) 0.088 (0.003) 0.17 (0.004)
94 169 6 21 0.12 0.11 (0.031) 0.13 (0.034) 0.081 (0.003) 0.179 (0.004)
94 214 6 12 0.11 0.05 (0.022) 0.21 (0.041) 0.09 (0.003) 0.157 (0.004)
84 167 6 23 0.10 0.09 (0.029) 0.12 (0.033) 0.103 (0.003) 0.147 (0.004)
79 174 7 10 0.12 0.17 (0.038) 0.13 (0.034) 0.086 (0.003) 0.171 (0.004)
95 203 7 9 0.09 0.1 (0.03) 0.16 (0.037) 0.085 (0.003) 0.134 (0.003)
75 152 8 9 0.13 0.1 (0.03) 0.12 (0.033) 0.083 (0.003) 0.175 (0.004)
78 149 8 16 0.12 0.08 (0.027) 0.21 (0.041) 0.088 (0.003) 0.171 (0.004)
76 142 8 22 0.12 0.07 (0.026) 0.17 (0.038) 0.098 (0.003) 0.156 (0.004)
80 140 9 17 0.13 0.04 (0.02) 0.2 (0.04) 0.084 (0.003) 0.176 (0.004)
81 146 9 12 0.14 0.14 (0.035) 0.18 (0.039) 0.079 (0.003) 0.181 (0.004)
97 190 10 5 0.14 0.07 (0.026) 0.27 (0.045) 0.072 (0.003) 0.178 (0.004)
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draws on established global optimisation algorithms which use statistical ‘sur-
rogate‘ models to solve design problems where there are several parameters to
be chosen, several objectives to minimise, and several constraints to satisfy. We
have illustrated how such problems arise in clinical trials of complex interven-
tions.
The general optimisation framework we have suggested recognises that in
many complex trials we are interested in minimising more than one quantity
subject to constraints on operating characteristics. Problems of this sort are
common in multilevel trial design [40], but are typically approached by first
reducing the multiple objectives down to a single objective. For example, in the
design of a cluster randomised trial it is common to fix the number of partici-
pants per cluster and minimise the number of clusters [41], or vice-versa [42, 43].
Alternatively, a function which specifies the cost of sampling at the cluster and
the patient level could be specified [44], and the overall cost minimised [45].
The latter approach has been suggested for both two-level [46] and three-level
hierarchical trial designs [47, 48]. However, the a priori specification of such a
cost function may not always be feasible, particularly when several stakeholders
are involved [49]. The Pareto optimisation framework we have described leads
to a more computationally challenging optimisation problem, but produces a
set of good solutions enabling the available trade-offs between objectives to be
seen and selected from.
As noted in Section 1, related work in simulation-based design methodology
has often focussed on a specific area of application. One advantage that brings
is the relative ease with which the software can be used to solve a new problem
within the same area. In contrast, our approach requires that the user provides a
program which simulates the data generation and analysis of their proposed trial
design. Although some have argued that this requirement may be prohibitive
in practice [8], it allows the user to solve their specific problem rather than
some related version of it. Moreover, prior to addressing the sample size issue,
modelling and simulation can help inform many other aspects of trial design,
such as the patient population or the choice of endpoint [50]. One way to assist
users in writing their own simulations is to share example programs for a range
of problems, providing a starting point for the development of a new program.
We have provided some examples in the appendix.
When submitting a proposed design for approval by a funding body it is im-
portant that the sample size calculation is transparent and replicable. This may
be achieved in the context of simulation-based SSD by supplying the simulation
program as part of the application [4]. Given this, any reviewer should be able
to re-calculate the operating characteristics of the proposed design. However,
a greater challenge for the reviewer is understanding the program and ensuring
it is an accurate representation of the model in question. This requirement has
partly motivated our use of R. Although significantly slower than a compiled
language such as C++, it has been argued that software written in R is more
transparent [50]. Validation will be further facilitated if a simulation protocol
of the sort described in [51] is provided alongside the code. Future work could
develop an interface for alternative statistical software such as Stata or SAS,
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allowing a simulation program to be written in them and connect with the R
implementation of the optimisation algorithm.
We have followed the conventional approach to clinical trial design whereby
constraints on operating characteristics are set and then a constrained optimi-
sation problem is solved. In practice the constraints are not fixed in advance,
but adjusted iteratively in response to the design requirements they produce.
For example, an initial nominal power of 90% may require an infeasibly large
sample size, leading to a revision down to 80%. Such an iterative procedure
will increase an already substantial computational burden for simulation-based
design. However, note that a change to a constraint does not mean starting the
process again, since any previous MC estimates can still be used when fitting
the GP model(s). The sequential nature of the optimisation algorithm suggests
that an interactive routine could be developed, where the user pauses the al-
gorithm in response to the sample size requirements which are being observed,
adjusts the constraints, and then continues with the optimisation.
The examples have demonstrated that the time required to solve a sample
size determination problem can be significant, of the order of hours. Given
that the majority of computational effort is expended generating MC samples
when evaluating solutions, it is important that these simulation programs are
as efficient as possible. We recommend making use of code profilers such as
R’s ‘Rprof’ to identify the parts of the program that are consuming the most
resources. Further efficiencies could potentially be gained by using more sophis-
ticated methods for surrogate modelling and efficient optimisation. For example,
when the modelled function can be assumed monotonic, this information can
be incorporated into the surrogate modelling process [23].
Numerous extensions to the proposed approach can be considered. One ar-
gument for simulation-based design is the ease with which sensitivity to model
assumptions, such as the value of nuisance parameters, can be assessed [2]. Fu-
ture work could consider how a systematic assessment of sensitivity to nuisance
parameters could be conducted, given a proposed trial design. Such investi-
gations fall under the heading of uncertainty quantification and can be carried
out using GP regression and associated techniques [52]. A further extension
could consider Bayesian approaches to trial design, including hybrid Bayesian-
frequentist assurances [53], fully Bayesian measures such as average coverage
criterion [54], and decision-theoretic methods [55]. Aside from very simple cases
involving only conjugate analyses, evaluating these Bayesian criteria will gener-
ally require simulation [53] and so optimal design may benefit from the efficient
methods discussed here. Complex SSD problems are also common in the area
of adaptive designs, which can aim to minimise the expected sample size under
several different hypotheses and over a number of stopping rule parameters [56].
Extending the proposed methods to such problems would require using sur-
rogate models to approximate the objective functions, as opposed to only the
constraints.
In conclusion, efficient optimisation algorithms based on surrogate models
of expensive operating characteristic functions can be used to solve complex
clinical trial sample size determination problems. By using these methods we
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can avoid making unrealistic simplifying assumptions at the trial design stage,
both in terms of the statistical model underlying the trial and of the nature of
the design problem.
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